Prolonged cetuximab treatment promotes p27
Autophagy
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cetuximab
/ administration & dosage
Cyclin-Dependent Kinase Inhibitor p27
/ genetics
ErbB Receptors
/ antagonists & inhibitors
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Microtubule-Associated Proteins
/ genetics
Phosphorylation
Proto-Oncogene Proteins c-akt
/ genetics
S-Phase Kinase-Associated Proteins
/ genetics
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
TOR Serine-Threonine Kinases
/ genetics
Treatment Outcome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 03 2021
04 03 2021
Historique:
received:
13
08
2020
accepted:
22
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is an efficient anti-tumor therapeutic agent that inhibits the activation of EGFR; however, data related to the cellular effects of prolonged cetuximab treatment are limited. In this study, the long-term cellular outcome of prolonged cetuximab treatment and the related molecular mechanism were explored in a head and neck squamous cell carcinoma cell line constitutively expressing a fluorescent ubiquitination-based cell cycle indicator. Fluorescent time-lapse imaging was used to assess clonal growth, cell motility, and cell-cycle progression. Western blot analysis was performed to measure the level of phosphorylation and protein-expression following cetuximab treatment. Over 5 days cetuximab treatment decreased cell motility and enhanced G1 phase cell arrest in the central region of the colonies. Significantly decreased phosphorylation of retinoblastoma, Skp2, and Akt-mTOR proteins, accumulation of p27
Identifiants
pubmed: 33664437
doi: 10.1038/s41598-021-84877-4
pii: 10.1038/s41598-021-84877-4
pmc: PMC7933308
doi:
Substances chimiques
CDKN1B protein, human
0
MAP1LC3B protein, human
0
Microtubule-Associated Proteins
0
S-Phase Kinase-Associated Proteins
0
Cyclin-Dependent Kinase Inhibitor p27
147604-94-2
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5259Références
Methods. 2017 Feb 15;115:80-90
pubmed: 27713081
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
Breast Cancer Res. 2006;8(4):R46
pubmed: 16859513
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Oncotarget. 2018 Apr 6;9(26):18099-18114
pubmed: 29719593
Cancer Metastasis Rev. 2005 Jan;24(1):9-17
pubmed: 15785869
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8832-7
pubmed: 24889617
BMC Res Notes. 2015 Jun 02;8:203
pubmed: 26032726
Cell Death Dis. 2013 Jun 27;4:e693
pubmed: 23807222
Int J Oncol. 2015 Dec;47(6):2165-72
pubmed: 26497980
Cancer Sci. 2017 Apr;108(4):704-712
pubmed: 28135769
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Cancer Immunol Immunother. 2017 May;66(5):573-579
pubmed: 28197666
Expert Rev Anticancer Ther. 2008 Mar;8(3):375-91
pubmed: 18366286
Cell. 2008 Feb 8;132(3):487-98
pubmed: 18267078
BMC Cancer. 2011 Sep 06;11:388
pubmed: 21896192
Cancer. 2005 Apr 1;103(7):1336-46
pubmed: 15717322
Cancer Res. 1987 Jul 1;47(13):3603-5
pubmed: 3581091
Cancer Res. 2001 Oct 1;61(19):7044-7
pubmed: 11585732
Mol Cell Biol. 2009 Jun;29(12):3332-43
pubmed: 19364817
Theranostics. 2016 May 24;6(8):1232-43
pubmed: 27279914
Jpn Dent Sci Rev. 2018 May;54(2):88-103
pubmed: 29755619
Drug Resist Updat. 2011 Dec;14(6):260-79
pubmed: 21920801
J Surg Oncol. 2019 May;119(6):685-686
pubmed: 30701564
BMC Pharmacol Toxicol. 2014 Nov 27;15:66
pubmed: 25428177
Cancer Res. 2014 May 15;74(10):2825-34
pubmed: 24648348
Oncol Lett. 2017 Feb;13(2):930-936
pubmed: 28356980
Cancer Chemother Pharmacol. 2018 Mar;81(3):549-554
pubmed: 29383483
Nat Cell Biol. 1999 Aug;1(4):193-9
pubmed: 10559916
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Int J Oral Maxillofac Surg. 2008 Sep;37(9):847-52
pubmed: 18620845
Radiat Res. 2020 Apr;193(4):305-317
pubmed: 32074012
Tumour Biol. 2018 Sep;40(9):1010428318800180
pubmed: 30226113
Oral Dis. 2015 Oct;21(7):815-25
pubmed: 24219320
J Oral Pathol Med. 2017 Jan;46(1):21-30
pubmed: 27229731
Head Neck Oncol. 2010 Apr 14;2:8
pubmed: 20398256
Oncology. 2002;63(1):92-8
pubmed: 12187077
N Engl J Med. 2008 Sep 11;359(11):1143-54
pubmed: 18784104
Eur J Cancer. 2010 Jun;46(9):1703-11
pubmed: 20399639
J Clin Oncol. 2008 Jan 20;26(3):374-9
pubmed: 18202412
Cancer Res. 2013 Jul 15;73(14):4267-77
pubmed: 23722550
Cancer Biol Ther. 2015;16(8):1252-8
pubmed: 26046389
Head Neck. 1991 Mar-Apr;13(2):132-9
pubmed: 2022478
BMC Med Genomics. 2010 May 04;3:14
pubmed: 20441585
Clin Cancer Res. 2001 Oct;7(10):2958-70
pubmed: 11595683
Nat Cell Biol. 2009 Apr;11(4):420-32
pubmed: 19270694
Am Soc Clin Oncol Educ Book. 2013;:246-55
pubmed: 23714515
Nat Med. 2013 May;19(5):538-40
pubmed: 23652103
Mol Cancer Ther. 2016 Aug;15(8):1988-97
pubmed: 27207775
Autophagy. 2010 Nov;6(8):1066-77
pubmed: 20864811
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Nat Cell Biol. 2009 Apr;11(4):397-408
pubmed: 19270695